Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1024 | 1040 | 1039 | 1111 | 1259 | 1759 |
Fund Return | 2.43% | 3.99% | 3.87% | 3.56% | 4.71% | 5.81% |
Place in category | 253 | 519 | 295 | 326 | 409 | 156 |
% in Category | 36 | 77 | 51 | 60 | 86 | 56 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 9.59B | 24.08 | 6.31 | 11.73 | ||
UBS CH Vitainvest 50 World U | 4.35B | 2.45 | -0.62 | 2.66 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.38B | 20.41 | 4.96 | 9.21 | ||
UBS CH Institutional Fund 2 EquiSCA | 2.8B | 11.47 | -1.07 | 6.69 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.8B | 11.68 | -0.82 | 6.98 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.31B | 9.28 | 2.17 | 6.28 | ||
Raiffeisen Futura Swiss Stock A | 2.12B | 7.92 | -0.59 | 6.39 | ||
CH0502155648 | 2.05B | 9.21 | 2.75 | - | ||
UBS CH Equity Fund Swiss Income CHQ | 2.05B | 2.59 | 4.20 | 6.41 | ||
Pictet CH Institutional Swiss EquiI | 1.69B | 11.30 | 1.45 | 7.20 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Roche Holding Participation | CH0012032048 | 9.77 | 254.30 | +1.27% | |
Nestle | CH0038863350 | 9.34 | 76.00 | +0.05% | |
Novartis | CH0012005267 | 9.33 | 92.85 | +1.41% | |
UBS Group | CH0244767585 | 9.03 | 28.21 | +0.25% | |
Zurich Insurance Group | CH0011075394 | 7.67 | 549.40 | +0.33% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Strong Sell | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review